Recent Progress in the Application of Tau Protein Biosensors for Diagnosis of Neurodegenerative Diseases

Abstract

The microtubule-associated Tau protein is found in the central nervous system (CNS) in six major isoforms. Neurodegenerative diseases have been linked to post-translational changes of Tau, most notably phosphorylation. Tau protein’s molecular diversity is highly helpful in the identification of neurodegenerative illnesses. Nonetheless, one major obstacle to the early detection of brain illness is the nanoscale identification of tau proteins. The standard methods for identifying tau protein include western blotting, polymerase chain reaction (PCR), and real-time PCR. Enzyme-linked immunosorbent assay (ELISA) is another approach used. The limited sensitivity and specificity of these detections, together with the need for sophisticated equipment, are some of their drawbacks. The development of innovative and complex methods for tau protein screening is necessary to address the aforementioned issues. Biosensors are a cutting-edge instrument that may help identify various neurodegenerative biomarkers as early as feasible. This paper provides an overview of the most recent developments in the detection of neurodegenerative diseases employing biosensors built on nanotechnology and methods for imaging, electrochemical, and optical detection of the Tau protein. Furthermore, we outline the present difficulties and suggest a possible course for biosensor-based detection and intervention in the future. Graphical Abstract: (Figure presented.)